Another strategy utilizes CRISPR-Cas9 base-editing to disrupt the LRF repressor binding site within HBG1/2 and observed an upregulation of HbF to over 20% of total hemoglobins in SCD HSPCs Antoniou et al., 2022. The gene discussed is HBG1; the disease is Schnyder corneal dystrophy.